Brocadisipal en es it fr

Brocadisipal Brand names, Brocadisipal Analogs

Brocadisipal Brand Names Mixture

  • No information avaliable

Brocadisipal Chemical_Formula


Brocadisipal RX_link

Brocadisipal fda sheet

Brocadisipal FDA

Brocadisipal msds (material safety sheet)

Brocadisipal MSDS

Brocadisipal Synthesis Reference

No information avaliable

Brocadisipal Molecular Weight

269.381 g/mol

Brocadisipal Melting Point

156-157 oC

Brocadisipal H2O Solubility

Sparingly soluble in water

Brocadisipal State


Brocadisipal LogP


Brocadisipal Dosage Forms

Tablet (extended-release)

Brocadisipal Indication

Indicated for the treatment of Parkinson's disease.

Brocadisipal Pharmacology

Orphenadrine is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute painful musculoskeletal conditions. Orphenadrine is an anticholinergic with a predominantly central effect and only a weak peripheral effect. In addition, it has mild antihistaminic and local anaesthetic properties. Parkinson's syndrome is the consequence of a disturbed balance between cholinergic and dopaminergic neurotransmission in the basal ganglia caused by a decrease in dopamine. Orphenadrine restores the physiological equilibrium and has a favourable effect on the rigidity and tremor of Parkinson's disease and Parkinsonian syndromes. The effect is somewhat less on bradykinesia.

Brocadisipal Absorption

Orphenadrine is almost completely absorbed in the gastrointestinal tract.

Brocadisipal side effects and Toxicity

Oral, mouse LD50 = 100 mg/kg; oral, rat LD50 = 255 mg/kg

Brocadisipal Patient Information

No information avaliable

Brocadisipal Organisms Affected

Humans and other mammals